非布索坦治疗痛风疗效如何？

For the treatment of chronic hyperuricemia (gout). Gout occurs because the body produces excessive blood uric acid and the kidneys' reduced ability to eliminate it. Blood uric acid accumulates in the body, causing urate crystals to accumulate in joints and internal organs.

According to officially released clinical trial data, the effectiveness of febuxostat in the general population is about 70%, which is much higher than that of allopurinol. Moreover, there is a clear difference between febuxostat and placebo, and febuxostat is safer. Clinical trial data on more than 3,000 people show that after taking febuxostat for six months, patients can effectively reduce uric acid in the blood to 360 μmol/L. It can be seen that the therapeutic effect of febuxostat is still very significant.

Not only that, but research results show that long-term use of febuxostat can maintain blood uric acid in most patients at ≤6.0mg/dl for a long time. Moreover, mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of febuxostat, which means that the uric acid-lowering effect of febuxostat is no different from that of patients with normal renal function, and its safety is good. According to experimental studies, it can be known that the therapeutic effect of febuxostat is better than placebo and has good clinical application prospects. 

However, some adverse reactions may occur when taking febuxostat. The most common adverse reactions are abnormal liver function, with an incidence rate of less than 7%, and nausea, joint pain, and rash, with an incidence rate of less than 2%. This data also shows that the human body has good tolerance to febuxostat and the drug is highly safe.

Patients should have a liver function test (serum alanine aminotransferase, aspartate transferase, alkaline phosphatase, and total bilirubin) performed before first starting febuxostat and use this result as a baseline level.

Febuxostat is now on the market in China and has been included in medical insurance, but the price is relatively expensive. The efficacy of febuxostat produced by Zydus Pharmaceuticals in India is the same as that of the original drug, and the price is indeed much lower, with high cost performance. The specification of generic drugs is 80mg*30 tablets/box, and its price is about 200$, which is acceptable to ordinary patients with a lot of prices. If patients have other questions about overseas purchases, they can consult Medical Companion Travel.